Neoadjuvant Chemotherapy in Invasive Bladder Cancer
1990
Neoadjuvant Chemotherapy in Invasive Bladder Cancer
publication
Evidence: moderate
Author Information
Author(s): Ted A.W. Splinter, Howard I. Scher, R.T.D. Oliver
Conclusion
The book highlights that while neoadjuvant chemotherapy shows promise, the overall 5-year survival rate for T3 bladder cancer remains low at 30%.
Supporting Evidence
- Complete remission rates for single agent platinum were 11%, while all platinum-based combinations exceeded 20%.
- The two drug combinations methotrexate cisplatin and the four drug Memorial M-VAC regimen had similar remission rates of 33% and 32%, respectively.
- 70-80% of patients remained tumor-free after TURT, but only 50% were tumor-free at 2 years post-treatment.
Takeaway
This book talks about how chemotherapy can help treat bladder cancer, but many patients still don't survive long-term.
Methodology
The book includes reviews and papers from various studies on chemotherapy and treatment responses.
Potential Biases
There may be bias due to the lack of information on tumor resection prior to treatment.
Limitations
The book raises many questions and lacks definitive data from randomized trials on response or survival.
Participant Demographics
The studies included participants from 12 different countries.
Want to read the original?
Access the complete publication on the publisher's website